Autolus Therapeutics plc

NasdaqGS:AUTL Stok Raporu

Piyasa değeri: US$745.1m

Autolus Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Autolus Therapeutics CEO'su Chris Itin, Mar2016 tarihinde atandı, in görev süresi 8.67 yıldır. in toplam yıllık tazminatı $ 2.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.5% maaş ve 77.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.4% ine doğrudan sahiptir ve bu hisseler $ 2.99M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 4.7 yıldır.

Anahtar bilgiler

Chris Itin

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi22.5%
CEO görev süresi8.7yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi3.1yrs
Yönetim Kurulu ortalama görev süresi4.7yrs

Son yönetim güncellemeleri

Recent updates

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 21

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Sep 06

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Autolus Therapeutics: Major Inflection Point On The Horizon

Jul 31

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

CEO Tazminat Analizi

Chris Itin'un ücretlendirmesi Autolus Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$270m

Jun 30 2024n/an/a

-US$234m

Mar 31 2024n/an/a

-US$221m

Dec 31 2023US$2mUS$551k

-US$208m

Sep 30 2023n/an/a

-US$158m

Jun 30 2023n/an/a

-US$155m

Mar 31 2023n/an/a

-US$152m

Dec 31 2022US$3mUS$502k

-US$149m

Sep 30 2022n/an/a

-US$164m

Jun 30 2022n/an/a

-US$155m

Mar 31 2022n/an/a

-US$146m

Dec 31 2021US$3mUS$543k

-US$142m

Sep 30 2021n/an/a

-US$143m

Jun 30 2021n/an/a

-US$147m

Mar 31 2021n/an/a

-US$145m

Dec 31 2020US$4mUS$522k

-US$142m

Sep 30 2020n/an/a

-US$140m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$127m

Dec 31 2019US$5mUS$517k

-US$124m

Sep 30 2019n/an/a

-US$104m

Jun 30 2019n/an/a

-US$89m

Mar 31 2019n/an/a

-US$68m

Dec 31 2018n/an/a

-US$58m

Sep 30 2018US$2mUS$403k

-US$45m

Tazminat ve Piyasa: Chris 'ın toplam tazminatı ($USD 2.45M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.20M ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Chris Itin (60 yo)

8.7yrs

Görev süresi

US$2,449,092

Tazminat

Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christian Itin
CEO & Director8.7yrsUS$2.45m0.40%
$ 3.0m
Martin Pule
Founder10.3yrsVeri yok0.26%
$ 2.0m
Robert Dolski
Senior VP & CFO1.3yrsVeri yokVeri yok
Christopher Vann
Senior VP & COO8.1yrsVeri yok0.042%
$ 314.2k
David Brochu
Senior VP & Chief Technical Officer3.8yrsVeri yok0%
$ 0
Alexander Swan
Senior VP & Chief Human Resources Officer3.1yrsVeri yok0%
$ 0
Brent Rice
Senior VPno dataVeri yok0.0035%
$ 26.3k
Olivia Manser
Director of Investor Relationsno dataVeri yokVeri yok
Alex Driggs
Senior VP of Legal Affairs & General Counsel and Secretary3.1yrsVeri yokVeri yok
Chris Williams
Senior VP & Chief Business Development Officerless than a yearVeri yok0.0031%
$ 23.0k
Miranda Neville
Senior Vice President of Project Management1.3yrsVeri yokVeri yok
Veronica Hersberger
Senior Vice President of Medical Affairs1.8yrsVeri yokVeri yok

3.1yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: AUTL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christian Itin
CEO & Director10.1yrsUS$2.45m0.40%
$ 3.0m
William Young
Independent Non-Executive Director3yrsUS$224.14k0%
$ 0
Michael Bonney
Chairman of the Boardless than a yearVeri yokVeri yok
Cynthia Butitta
Independent Non-Executive Director6.7yrsUS$209.89k0.0038%
$ 28.0k
John Berriman
Independent Non-Executive Director10.3yrsUS$207.98k0.051%
$ 381.7k
Martin Murphy
Independent Non-Executive Director10.2yrsUS$201.77k0%
$ 0
Joseph Anderson
Independent Non-Executive Director8.8yrsUS$207.98k0%
$ 0
Linda Bain
Independent Non-Executive Director6.4yrsUS$216.11k0%
$ 0
Robert Azelby
Non-Executive Directorless than a yearVeri yok0%
$ 0
Robert Iannone
Non-Executive Director1.4yrsUS$171.92k0%
$ 0
Ravi Rao
Non-Executive Directorless than a yearVeri yokVeri yok
Elisabeth Leiderman
Non-Executive Directorless than a yearUS$16.22k0%
$ 0

4.7yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AUTL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).